Jason Bock

CTMC CEO, Cell therapy enthusiast, Houston convert

[Jason Bock @jbbock]

@zroger73 @SawyerMerritt That’s been our experience too. We had several generations of Civics, Accords and Odessys. Honda used to make very dependable if not flashy vehicles. They seem to have lost their way 10-15 years ago.

[Jason Bock @jbbock]

@RySciComms That’s true dedication Ryan.

[Jason Bock @jbbock]

@JEBistline The trends for AI data centers will follow these curves. Energy generation is the bottleneck and Texas seems to be leading the way to remove this bottleneck. Such data centers will be a boon to local economies if they can be powered without overly straining the grid.

[Jason Bock @jbbock]

@UTMDAnderson ….and this is the first, singly-edited TIL from KSQ. Even more to come with the first doubly-edited TIL, KSQ-004.

[Jason Bock @jbbock]

@PavlosMsaouel @UTMDAnderson @IamLinghua @AACR @VivekSubbiah @PGrivasMDPhD @neerajaiims @kidneycoa @kidneycan @KidneyCancer @kcCURE @QingZhangLab @panos_konto @OncHahn This is the result of great mentorship and a strong institution. Well done Pavlos.

[Jason Bock @jbbock]

@Mykalt45 Truly awesome news MIchael and the Crossbridge team.

[Jason Bock @jbbock]

@Nature @RySciComms Another example of the impact of Cell Therapy. This patient’s entire life has been changed by a single dose. She went from daily blood transfusions to having her life back. That’s ideally how medicines should work.

[Jason Bock @jbbock]

@mukundiyngr I believe the improvement in melanoma is just as significant where immunotherapies have been transformation for a formerly difficult to treat solid tumor.

[Jason Bock @jbbock]

@PeterDiamandis The concept of designing your business for an age of abundance caught my attention. When we reach such abundance (by 2030?!) I can’t help but believe that demand will explode for next generation, single-dose, curative cell and gene therapies that may be cost prohibitive today…

[Jason Bock @jbbock]

@JacobPlieth Interesting play

[Jason Bock @jbbock]

@US_FDA So glad to see new focus on Biosimilar regulatory red tape. There is no doubt that needless regulatory hurdles hamstrung biosimilars in the US. A vibrant biosimilar ecosystem will lower healthcare costs and stimulate innovation.

[Jason Bock @jbbock]

@BenjaminBadejo Whether by an intentional strategy or luck, Apple is now positioned so well to play in the AI race with local models running on Mac minis and Studios. The next version of the Studio with M5 together with the new mini open source models will be a game changer.

[Jason Bock @jbbock]

@Yellow_Dog1959 @APompliano @elonmusk Luck is where Preparation meets Opportunity.

[Jason Bock @jbbock]

@mikepat711 Huge Tesla supporter. But do we know enough about BYD financials to add them to this insightful chart?

[Jason Bock @jbbock]

@OwenGregorian I for one am exciting to see a government agency embracing a forward-looking perspective. Yes you will need proper oversight especially in the beginning. This is how we advance. Taking 12 months for humans to review 10s of 1000s of pages of data seems archaic and slow.

[Jason Bock @jbbock]

@StockSavvyShay Yahoo is still on the list??

[Jason Bock @jbbock]

@GreenLymphoLab @dgermain21 @icmlugano @washumedicine @MDAndersonNews Great stuff! This is how we start to better target cell therapies to the patients who will derive the most value from them.

[Jason Bock @jbbock]

@BiotechTVHQ @LegendBiotech What amazing results! I especially appreciated the health economics segment. 25 months after carvyti vs standard of care the costs were $0.7M vs $1.6. Plus carvyti is of course one and done, while the SoC has frequent treatments. Cell therapy is revolutionary.

[Jason Bock @jbbock]

@ScottAdamsSays Awesome initiative for MIT and the US.

[Jason Bock @jbbock]

@JacobPlieth @ApexOnco Not all TIL are created (manufactured) equally….